BIOMAT Database Logo BIOMAT Database Logo

[Clinical and hemostatic evaluation of curantyl in hypertensives]. 1991

Ia M Ena, and L A Didkovskaia

Curantyl supplemented to the multimodality therapy for patients with Stage II essential hypertension with uncomplicated events or complicated by hypertensive crisis was ascertained to lower the intensity of intravascular blood microcoagulation due to its modifying effect on the procoagulative and thrombocytic links of hemostasis and blood fibrinolytic activity. The drug exerted no marked positive action on clinical manifestations of the disease and caused no significant changes in the parameters of hemostatic procoagulative and thrombocytic links and blood fibrinolytic activity.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006487 Hemostasis The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION. Hemostases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Ia M Ena, and L A Didkovskaia
Clinical evaluation of Declinax in Nigerian hypertensives.
June 1970, The British journal of clinical practice,
Ia M Ena, and L A Didkovskaia
Clinical evaluation of hemostatic molecular markers.
December 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Ia M Ena, and L A Didkovskaia
[Use of curantyl in nephritis].
February 1988, Klinicheskaia meditsina,
Ia M Ena, and L A Didkovskaia
[Use of curantyl in diffuse glomerulonephritis].
May 1977, Klinicheskaia meditsina,
Ia M Ena, and L A Didkovskaia
[Quantitative spectrophotometric determination of curantyl].
January 1977, Farmatsevtychnyi zhurnal,
Ia M Ena, and L A Didkovskaia
[Preparation and hemostatic evaluation of chitosan composite hemostatic membrane].
March 2010, Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery,
Ia M Ena, and L A Didkovskaia
[Biomarker for evaluation and management of hypertensives].
November 2015, Nihon rinsho. Japanese journal of clinical medicine,
Ia M Ena, and L A Didkovskaia
A new surgical absorbable hemostatic agent. Experimental and clinical evaluation.
September 1960, American journal of surgery,
Ia M Ena, and L A Didkovskaia
[The Hemostatic Effect and Safety Evaluation Tests of Soluble Hemostatic Gauze].
November 2016, Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation,
Ia M Ena, and L A Didkovskaia
[Effect of curantyl, corhormone and sustac on myocardial function].
May 1977, Vrachebnoe delo,
Copied contents to your clipboard!